Pharma generics have given great returns in the last 18 months. Hard to see that play out in the next 12 months given gRevlimid will go off patent. 

Theme for this year could be long #Biosimilars, #CRDMO or #CDMO and short US generics.
#Biosimilars #CRDMO #CDMO